Skip to contentB
Biolargo, Inc.
B
BLGOBiolargo, Inc. Q4 2020 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$909.00K$909.00Kderived+69.3% vs Q4 2019 Net Income-$1.99M-$1.99MderivedN/M vs Q4 2019 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Biolargo, Inc. · CIK 880242 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$467,000+68.0% Operating Incomederived-$1,967,000N/M Operating Cash Flowderived-$836,000N/M Margins · derivedGross margin51.4%−0.4 pt vs Q4 2019
Operating margin-216.4%+93.3 pt vs Q4 2019
Net margin-219.4%+305.4 pt vs Q4 2019
ended Dec 31, 2020 · filed Mar 30, 2021 · 89 d after period end